In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development

被引:42
|
作者
Tsapogas, Panagiotis [1 ]
Swee, Lee Kim [2 ]
Nusser, Anja [1 ]
Nuber, Natko [1 ]
Kreuzaler, Matthias [1 ]
Capoferri, Giuseppina [1 ]
Rolink, Hannie [1 ]
Ceredig, Rhodri [3 ]
Rolink, Antonius [1 ]
机构
[1] Univ Basel, Dept Biomed, CH-4003 Basel, Switzerland
[2] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[3] Natl Univ Ireland, Regenerat Med Inst, Dept Physiol, Sch Med Nursing & Hlth Sci, Galway, Ireland
基金
瑞士国家科学基金会;
关键词
COMMON LYMPHOID PROGENITORS; INTERNAL TANDEM DUPLICATION; DENDRITIC CELLS; STEM-CELL; MURINE FLT3; SELF-RENEWAL; RECEPTOR; EXPRESSION; EXPANSION; IDENTIFICATION;
D O I
10.3324/haematol.2013.089482
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytokines are essential regulators of hematopoiesis, acting in an instructive or permissive way. Fms-like tyrosine kinase 3 ligand (FLT3L) is an important cytokine for the development of several hematopoietic populations. Its receptor (FLT3) is expressed on both myeloid and lymphoid progenitors and deletion of either the receptor or its ligand leads to defective developmental potential of hematopoietic progenitors. In vivo administration of FLT3L promotes expansion of progenitors with combined myeloid and lymphoid potential. To investigate further the role of this cytokine in hematopoietic development, we generated transgenic mice expressing high levels of human FLT3L. These transgenic mice displayed a dramatic expansion of dendritic and myeloid cells, leading to splenomegaly and blood leukocytosis. Bone marrow myeloid and lymphoid progenitors were significantly increased in numbers but retained their developmental potential. Furthermore, the transgenic mice developed anemia together with a reduction in platelet numbers. FLT3L was shown to rapidly reduce the earliest erythroid progenitors when injected into wild-type mice, indicating a direct negative role of the cytokine on erythropoiesis. We conclude that FLT3L acts on multipotent progenitors in an instructive way, inducing their development into myeloid/lymphoid lineages while suppressing their megakaryocyte/erythrocyte potential.
引用
收藏
页码:638 / 646
页数:9
相关论文
共 50 条
  • [21] Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
    Nazha, Aziz
    Cortes, Jorge
    Faderl, Stefan
    Pierce, Sherry
    Daver, Naval
    Kadia, Tapan
    Borthakur, Gautam
    Luthra, Raja
    Kantarjian, Hagop
    Ravandi, Farhad
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (08): : 1242 - 1245
  • [22] FMS-Like Tyrosine Kinase 3 Ligand Treatment Does Not Ameliorate Experimental Rapidly Progressive Glomerulonephritis
    Ghali, Joanna R.
    O'Sullivan, Kim M.
    Eggenhuizen, Peter J.
    Holdsworth, Stephen R.
    Kitching, A. Richard
    PLOS ONE, 2015, 10 (04):
  • [23] Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses
    Pais, Roshan
    Omosun, Yusuf
    Igietseme, Joseph U.
    Fujihashi, Kohtaro
    Eko, Francis O.
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [24] FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
    Novatcheva, Elli D.
    Anouty, Yasmine
    Saunders, Ila
    Mangan, James K.
    Goodman, Aaron M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03) : E161 - E184
  • [25] FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia
    Parcells, Bertrand W.
    Ikeda, Alan K.
    Simms-Waldrip, Tiffany
    Moore, Theodore B.
    Sakamoto, Kathleen M.
    STEM CELLS, 2006, 24 (05) : 1174 - 1184
  • [26] Hosts lacking fms-like tyrosine kinase 3 ligand exhibit marked reductions in transplant vascular sclerosis
    Wang, ZL
    Taner, T
    Morelli, AE
    Thomson, AW
    TRANSPLANTATION, 2005, 79 (08) : 869 - 875
  • [27] Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)
    Ma, Fei
    Liu, Peng
    Lei, Min
    Liu, Jian
    Wang, Hongtao
    Zhao, Shaohua
    Hu, Lihong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 127 : 72 - 86
  • [28] Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment
    Swee, Lee Kim
    Bosco, Nabil
    Malissen, Bernard
    Ceredig, Rhodri
    Rolink, Antonius
    BLOOD, 2009, 113 (25) : 6277 - 6287
  • [29] FMS-Like Tyrosine Kinase 3 Ligand Treatment of Mice Aggravates Acute Lung Injury in Response to Streptococcus pneumoniae: Role of Pneumolysin
    Brumshagen, Christina
    Maus, Regina
    Bischof, Andrea
    Ueberberg, Bianca
    Bohling, Jennifer
    Osterholzer, John J.
    Ogunniyi, Abiodun D.
    Paton, James C.
    Welte, Tobias
    Maus, Ulrich A.
    INFECTION AND IMMUNITY, 2012, 80 (12) : 4281 - 4290
  • [30] Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
    Pemmaraju, Naveen
    Kantarjian, Hagop
    Andreeff, Michael
    Cortes, Jorge
    Ravandi, Farhad
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (07) : 943 - 954